Ramin Ebrahimi

Ramin Ebrahimi

Auto-generated profile, based on publicly available information

Ramin Ebrahimi

Department of Radiology, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2005 in The Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
BKBrian P. Kearney
Brian P. Kearney
Srinivasan RamanathanSrinivasan Ramanathan
Srinivasan Ramanathan
ACAndrew K. Cheng
Andrew K. Cheng
RERamin Ebrahimi
Ramin Ebrahimi
JSJaymin Shah
Jaymin Shah

29 September 2022 in Radiology Case Reports
Verified
Journal Article
Open access
RERamin Ebrahimi
Ramin Ebrahimi
ASAmir Sajjad Mounesi Sohi
Amir Sajjad Mounesi Sohi
AMAli Mirsardoo
Ali Mirsardoo
NMNima Moosavi
Nima Moosavi
MKMohammad Saeid Khonji
Mohammad Saeid Khonji
Primary intradural extramedullary Ewing sarcoma (IEES) is the rarest type of Ewing sarcoma. Extreme caution is required for the diagnosis of IEES because benign intradural spinal tumors can be mistaken for IEES in the early stages of imaging and clinical evaluation. IEES tumors have no standardized treatment guidelines because of the lack of research on the therapeutic aspects of these tumors. Herein, we present a case of primary IEES in a male adolescent with a fast progression of the disease. Diagnosis of IEES was suspected with imaging (computed tomography scan and lumbosacral magnetic resonance imaging) and was confirmed with histology and immunohistochemistry (positive reactivity for CD99 and FLI1). He was successfully treated with surgical intervention with no radiotherapy or chemotherapy. Imaging studies are helpful in making the initial diagnosis of intradural extramedullary Ewing sarcoma. Surgery is considered to be a successful method of treatment for this condition.

25 September 2023 in Radiology Case Reports
Verified
Journal Article
Open access
RERamin Ebrahimi
Ramin Ebrahimi
ASAmir Sajjad Mounesi Sohi
Amir Sajjad Mounesi Sohi
MKMohammad Saeid Khonji
Mohammad Saeid Khonji
KGKimia Ghafouri
Kimia Ghafouri
Proliferative myositis (PM) is a benign intramuscular tumor that might mimic a malignant one due to its unusual pseudosarcomatous inflammatory nature. In this report, we describe a patient who developed PM after vaccination with Sinopharm coronavirus disease (COVID-19) vaccine. A 73 years old man was admitted due to rapidly-growing painful mass in his left thigh from a few days ago, curtailing his walking. He received a recent COVID-19 vaccination (Sinopharm COVID-19 vaccine) about 5 days before the beginning of symptoms. No history of trauma was present. On physical exam, a round firm mass was found in lateral side of mid portion of left thigh within the muscle with tenderness on palpation. An oval-shaped well-defined intramuscular mass measured 15 × 41 mm was noted in vastus lateralis muscle in ultrasonography. Left thigh magnetic resonance imaging (MRI) showed a well-defined intramuscular mass with a definite margin of 19 × 39 mm. Finally, ultrasound (US)-guided core needle biopsy showed muscular tissue with a loose mass composed of plump fibroblasts and myofibroblasts and large ganglion-like cell with abundant amphophilic to basophilic cytoplasm, vesicular nuclei and prominent nucleoli. Pathology report showed a very rare case identified as proliferative myositis. It should be noted that we cannot make a direct link between these 2 events. PM is an extremely rare entity; however, its relation with COVID-19 vaccination might be a coincidence.

12 October 2021 in Egyptian Journal of Radiology and Nuclear Medicine
Verified
Journal Article
Open access
PDF file
NRNima Rakhshankhah
Nima Rakhshankhah
RERamin Ebrahimi
Ramin Ebrahimi
MKManizhe Ataee Kachuee
Manizhe Ataee Kachuee
MMMohammad-Ali Mohammadi-Vajari
Mohammad-Ali Mohammadi-Vajari
AAAbolfazl Abouie
Abolfazl Abouie
Background: Maldescended ovaries are a rare condition. Despite its different embryologic development with the uterus, maldescended ovary is usually accompanied by uterine malformations and is found during the course of infertility. In other cases, it may be incidentally diagnosed in examinations due to abdominal pain or in a survey of finding paraneoplastic origin. Probable immune-related developmental conditions are associated with this abnormality; sometimes cross-reaction with other immune-related diseases is possible. Case presentation: Here, the probable paraneoplastic origin is surveyed for a patient with coexisting inflammatory myositis and myasthenia gravis. According to this survey non recognized Mullerian duct and ovarian anomalies were found. Conclusions: Knowledge about this anatomical abnormality is helpful for clinicians to prevent misdiagnosis and improper management. Moreover, understanding the probability of accompanying other conditions such as immune-related and neuromuscular junction disorders with Mullerian duct anomalies can offer a comprehensive insight.

1 November 2021 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
MRMoti Ramgopal
Moti Ramgopal
PRPeter Ruane
Peter Ruane
YSYongwu Shao
Yongwu Shao
RERamin Ebrahimi
Ramin Ebrahimi
AKAlex Kintu
Alex Kintu
KMKaram Mounzer
Karam Mounzer
In DISCOVER, a multinational randomized controlled trial, F/TAF demonstrated noninferior efficacy compared to F/TDF for HIV prevention with improved bone mineral density and renal safety biomarkers at the primary endpoint (when all participants had reached 48 weeks and 50% had reached 96 weeks) and at week (W) 96, the end of the blinded phase. We now report W144 outcomes for participants who were randomized to F/TAF and continued F/TAF in the open-label extension (OLE) phase. All participants who completed the randomized blinded phase could opt to receive F/TAF for at least 48 weeks in the OLE phase. We evaluated HIV incidence in participants on F/TAF through W144 and assessed changes in hip and spine bone mineral density (BMD) and in glomerular function (eGFR) from baseline to W144. 2,080 of the 2,694 participants initially randomized to F/TAF opted into the OLE phase, and 1,933 were still on study drug through W144, thereby leading to a total of 7,885 person-years (PY) of follow-up on F/TAF. Eight participants taking F/TAF acquired HIV in the blinded phase and 3 in the OLE phase. Dried blood spot analyses on the 3 OL infections found tenofovir diphosphate levels consistent with low adherence. Genotypic resistance testing showed no relevant resistance mutations for the 3 new infections. Among participants taking F/TAF, HIV incidence was 0.16/100 PY (95% CI 0.06-0.33) at the primary endpoint, 0.16/100 PY (95% CI 0.07-0.31) through 96 weeks and 0.14/100 PY (95% CI 0.07-0.25) through 144 weeks. Participants taking F/TAF had increases in hip BMD (mean percentage change +0.54%) and in spine BMD (mean percentage change +1.02%) from baseline to W144 (Figure 1). Median eGFR increased over 144 weeks, with a median increase of 2.6 mL/min from baseline to week 144. Participants in the F/TAF arm gained a median 2.3 kg (IQR -0.9-5.8) over 3 years of follow up. Figure 1. Changes in hip and spine bone mineral density and in eGFR through Week 144 The OLE of DISCOVER allowed for a long-term assessment (144 wks.) of F/TAF for PrEP. HIV incidence remained low with BMD and renal function parameters remaining stable through 144 weeks of follow-up. These findings demonstrate that F/TAF is a safe and effective option for long-term use in people who would benefit from PrEP. Moti Ramgopal, MD FACP FIDSA, Abbvie (Scientific Research Study Investigator, Speaker’s Bureau)Gilead (Consultant, Scientific Research Study Investigator, Speaker’s Bureau)Janssen (Consultant, Scientific Research Study Investigator, Research Grant or Support, Speaker’s Bureau)Merck (Consultant, Scientific Research Study Investigator)ViiV (Consultant, Scientific Research Study Investigator, Speaker’s Bureau) Peter Ruane, MD, AbbVie (Consultant, Research Grant or Support)Allergan (Research Grant or Support)Gilead Sciences Inc. (Consultant, Research Grant or Support, Shareholder, Speaker’s Bureau)Merck (Consultant, Research Grant or Support)ViiV Healthcare (Consultant, Research Grant or Support) Yongwu Shao, PhD, Gilead Sciences Inc. (Employee, Shareholder) Ramin Ebrahimi, MSc, Gilead Sciences Inc. (Employee, Shareholder) Alex Kintu, MD, ScD, Gilead Sciences Inc. (Employee, Shareholder) Christoph C. Carter, MD, Gilead Sciences Inc. (Employee, Shareholder) Moupali Das, MD, Gilead Sciences Inc. (Employee, Shareholder) Jared Baeten, MD, PHD, Gilead Sciences Inc. (Employee, Shareholder) Cynthia Brinson, MD, Abbvie (Scientific Research Study Investigator)BI (Scientific Research Study Investigator)Gilead Sciences Inc. (Scientific Research Study Investigator, Advisor or Review Panel member, Speaker’s Bureau, Personal fees)GSK (Scientific Research Study Investigator)Novo Nordisk (Scientific Research Study Investigator)ViiV Healthcare (Scientific Research Study Investigator, Advisor or Review Panel member, Speaker’s Bureau) Peter Shalit, MD, PhD, Abbvie (Grant/Research Support)Gilead Sciences (Consultant, Grant/Research Support, Speaker’s Bureau)Glaxo Smithkline (Consultant, Grant/Research Support)Janssen (Consultant, Grant/Research Support, Speaker’s Bureau)Merck (Grant/Research Support, Speaker’s Bureau)Thera (Speaker’s Bureau)ViiV Healthcare (Speaker’s Bureau) Karam Mounzer, MD, Epividian (Advisor or Review Panel member)Gilead Sciences Inc. (Consultant, Scientific Research Study Investigator, Research Grant or Support, Speaker’s Bureau)Janssen (Consultant, Research Grant or Support, Speaker’s Bureau)Merck (Research Grant or Support, Speaker’s Bureau)ViiV Healthcare (Consultant, Speaker’s Bureau)

1 October 2020 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
EDEric Daar
Eric Daar
JBJason Brunetta
Jason Brunetta
ECEric Cua
Eric Cua
JFJason Flamm
Jason Flamm
DADavid Asmuth
David Asmuth
ACAmanda Clarke
Amanda Clarke
In DISCOVER, emtricitabine/tenofovir alafenamide (F/TAF) was noninferior to F/tenofovir disoproxil fumarate (TDF) for preexposure prophylaxis (PrEP) in men who have sex with men and transgender women, with a superior renal laboratory profile. The differential impact of F/TAF and F/TDF on renal parameters among older individuals and those with medical comorbidities is unknown. DISCOVER randomized participants 1:1 to daily blinded F/TAF or F/TDF. We examined renal outcomes at week 48 including estimated glomerular filtration rate (eGFR) by Cockcroft-Gault, β2 microglobulin (M):Creatinine (Cr) and retinol binding protein (RBP):Cr ratios (markers of proximal renal tubular function), and discontinuations due to investigator reported study drug-related renal adverse events (AEs). Median age was 34 years (yrs)(range 18-76), with 12.5% vs 10.9% < 25yrs, 12.2% vs 14.4% ≥ 50yrs, and 1.1% vs 0.9% > 65yrs for F/TAF and F/TDF, respectively. The prevalence of medical comorbidities at baseline were; eGFR < 90mL/min= 9.1% vs 9.3%, diabetes= 2.9% vs 3.3%, and hypertension= 10.5 vs 11.1%, for F/TAF and F/TDF, respectively. eGFR changes by age category and medical comorbidity status are found in the Table. Forty participants had study drug-related renal AEs; 14 with F/TAF and 26 with F/TDF. Of these, 25% were > 50yrs, 20% had baseline eGFR < 90mL/min, 7.5% had history of diabetes, and 22.5% had history of hypertension. β2M:Cr and RBP:Cr changes were more favorable in participants receiving F/TAF, with greater magnitude of difference in older participants (data not shown). Table. The DISCOVER trial allows for a large single variable comparison of the two tenofovir prodrugs in the absence of underlying HIV infection and in the absence of third antiretroviral agents. F/TAF was associated with favorable changes in renal biomarkers regardless of age or medical comorbidity. Participants ≥50yrs or with comorbidities were proportionately more likely to develop study drug related renal AEs, but these were present in the minority of cases. Eric Daar, MD, BMS (Consultant)Gilead Sciences Inc. (Consultant, Grant/Research Support, Scientific Research Study Investigator)Janssen (Consultant)Merck (Consultant, Grant/Research Support)Teva (Consultant)Theratechnology (Consultant)Viiv Healthcare (Consultant, Grant/Research Support) Jason Brunetta, MD, AbbVie (Consultant)Gilead Sciences Inc. (Consultant, Grant/Research Support, Scientific Research Study Investigator, Speaker’s Bureau, Other Financial or Material Support, Conference attendance sponsorship)Janssen (Other Financial or Material Support, Conference attendance sponsorship)Merck (Consultant, Speaker’s Bureau, Other Financial or Material Support, Conference attendance sponsorship)Viiv Healthcare (Consultant, Speaker’s Bureau, Other Financial or Material Support, Conference attendance sponsorship) Eric Cua, MD, Gilead Sciences Inc. (Scientific Research Study Investigator) David Asmuth, MD, Gilead Sciences Inc. (Scientific Research Study Investigator) Christoph C. Carter, MD, Gilead Sciences Inc. (Employee, Shareholder) Yongwu Shao, PhD, Gilead Sciences Inc. (Employee, Shareholder) Pamela Wong, MPH, Gilead Sciences Inc. (Employee, Shareholder) Ramin Ebrahimi, MSc, Gilead Sciences Inc. (Employee, Shareholder) Moupali Das, MD, Gilead Sciences Inc. (Employee, Shareholder) Diana M. Brainard, MD, Gilead Sciences (Employee) Amanda Clarke, MD, Gilead Sciences Inc. (Consultant, Scientific Research Study Investigator, Other Financial or Material Support, Conference attendance sponsorship)Viiv Healthcare (Consultant, Other Financial or Material Support, Conference travel sponsorship)